Hungerhuber E. Carcinomas of the upper urinary tract: with early diagnosis 80-100% of patients survive 5 years [in German]. MMW Fortschr Med. 2003;145(5):32-35.
2.
Degtyar P, Neulander E, Zirkin H, et al. Fluorescence in situ hybridization performed on exfoliated urothelial cells in patients with transitional cell carcinoma of the bladder. Urology. 2004;63:398-401.
3.
Cheng L, Bostwick DG, Li G, Zhang S, Vortmeyer AO, Zhuang Z. Conserved genetic findings in metastatic bladder cancer: a possible utility of allelic loss of chromosomes 9p21 and 17p13 in diagnosis. Arch Pathol Lab Med. 2001;125:1197-1199.
4.
Kirkali Z, Tuzel E. Transitional cell carcinoma of the ureter and renal pelvis. Crit Rev Oncol Hematol. 2003;47:155-169.
5.
Zeegers MP, Kellen E, Buntinx F, van den Brandt PA. The association between smoking, beverage consumption, diet and bladder cancer: a systematic literature review. World J Urol. 2004;21:392-401.
6.
Tripathi A, Folsom AR, Anderson KE. Risk factors for urinary bladder carcinoma in postmenopausal women. The Iowa Women’s Health Study. Cancer. 2002;95:2316-2323.
7.
Tsukino H, Nakao H, Kuroda Y, et al. Glutathione S-transferase (GST) M1, T1 and N-acetyltransferase 2 (NAT2) polymorphisms and urothelial cancer risk with tobacco smoking. Eur J Cancer Prev. 2004;13:509-514.
8.
Aveyard P, Adab P, Cheng KK, Wallace DM, Hey K, Murphy MF. Does smoking status influence the prognosis of bladder cancer? A systematic review. BJU Int. 2002;90:228-239.
9.
Shvarts O, Han KR, Seltzer M, Pantuck AJ, Belldegrun AS. Positron emission tomography in urologic oncology. Cancer Control. 2002;9:335-342.
10.
Strong DW, Pearse H. Recurrent urothelial tumors following surgery for transitional cell carcinoma of the upper urinary tract. Cancer. 1976;5:2173-2183.
11.
Kakizoe T, Fujita J, Murase T, Matsumoto K, Kishi K. Transitional cell carcinoma of the bladder in patients with renal pelvic and ureteral cancer. J Urol. 1980;124:17-19.
12.
Pollack HM, Banner MP, Popky GL. Radiologic evaluation of the ureteral stump. Radiology. 1982;144:225-230.
13.
Holmang S, Johansson SL. Synchronous bilateral ureteral and renal pelvic carcinomas: incidence, etiology, treatment and outcome. Cancer. 2004;101:741-747.
Zungri E, Chechile G, Algaba F, Diaz I, Vila F, Castro Z. Treatment of transitional carcinoma of the ureter: is the controversy justified?Eur Urol. 1990;17:276-280.
16.
Sylvester RJ, Oosterlinck W, van der Meijden AP. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol. 2004;171(6 pt 1):2186-2190.
Sylvester RJ, van der Meijden AP, Lamm DL. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol. 2002;168: 1964-1970.
19.
Lamm DL, Blumenstein BA, Crissman JD, et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol. 2000;163:1124-1129.
20.
Lamm DL, Riggs DR, Shriver JS, van Gilder PF, Rach JF, Dehaven JI. Megadose vitamins in bladder cancer: a doubleblind clinical trial. J Urol. 1994;151:21-26.
21.
Calabro F, Sternberg CN. New drugs and new approaches for the treatment of metastatic urothelial cancer. World J Urol. 2002;20:158-166.
22.
Sternberg CN, Vogelzang NJ. Gemcitabine, paclitaxel, pemetrexed and other newer agents in urothelial and kidney cancers. Crit Rev Oncol Hematol. 2003;46(suppl):S105-S115.
23.
Chester JD, Hall GD, Forster M, Protheroe AS. Systemic chemotherapy for patients with bladder cancer: current controversies and future directions. Cancer Treat Rev. 2004;30:343-358.
24.
Scher H, Bahnson R, Cohen S, et al. NCCN urothelial cancer practice guidelines. National Comprehensive Cancer Network. Oncology (Huntingt).1998;12(7A):225-271.
